Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
2,666,933
-
Total 13F shares
-
37,983
-
Share change
-
+20,643
-
Total reported value
-
$92,809
-
Price per share
-
$2.45
-
Number of holders
-
6
-
Value change
-
+$15,777
-
Number of buys
-
5
-
Number of sells
-
2
Institutional Holders of LIXTE BIOTECHNOLOGY HOLDINGS, INC. - Common Stock, par value $0.0001 per share (LIXT) as of Q3 2023
As of 30 Sep 2023,
LIXTE BIOTECHNOLOGY HOLDINGS, INC. - Common Stock, par value $0.0001 per share (LIXT) was held by
6 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
37,983 shares.
The largest 6 holders included
Ethos Financial Group, LLC, MORGAN STANLEY, FNY Investment Advisers, LLC, Tower Research Capital LLC (TRC), WELLS FARGO & COMPANY/MN, and JPMORGAN CHASE & CO.
This page lists
6
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.